Pharvaris (NASDAQ:PHVS) Sees Significant Increase in Short Interest

Pharvaris (NASDAQ:PHVS - Get Free Report) was the target of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 311,100 shares, a growth of 99.4% from the January 15th total of 156,000 shares. Based on an average daily trading volume, of 64,900 shares, the days-to-cover ratio is presently 4.8 days. Approximately 1.8% of the company's shares are short sold.

Wall Street Analysts Forecast Growth

Separately, JMP Securities lifted their target price on Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a report on Friday, January 31st.

Pharvaris Stock Performance

Pharvaris stock traded down $0.10 during midday trading on Monday, reaching $17.27. The stock had a trading volume of 65,280 shares, compared to its average volume of 47,045. Pharvaris has a 1-year low of $15.21 and a 1-year high of $28.84. The firm's fifty day simple moving average is $18.30 and its 200-day simple moving average is $19.35. The stock has a market capitalization of $903.05 million, a P/E ratio of -6.17 and a beta of -3.08.

Institutional Trading of Pharvaris

Hedge funds and other institutional investors have recently made changes to their positions in the business. Patient Square Capital LP bought a new position in Pharvaris in the third quarter valued at $4,488,000. FMR LLC grew its stake in Pharvaris by 3.6% in the fourth quarter. FMR LLC now owns 5,395,370 shares of the company's stock valued at $103,429,000 after purchasing an additional 189,714 shares in the last quarter. Octagon Capital Advisors LP increased its position in shares of Pharvaris by 25.4% during the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock worth $14,914,000 after purchasing an additional 157,530 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Pharvaris by 36.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock worth $8,510,000 after purchasing an additional 118,408 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Pharvaris by 483.9% in the 4th quarter. Northern Trust Corp now owns 91,932 shares of the company's stock valued at $1,762,000 after buying an additional 76,188 shares during the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.